Breakout Setups
SRRK appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
SCHOLAR ROCK HOLDING CORP (SRRK) Stock Price & Overview
NASDAQ:SRRK • US80706P1030
Current stock price
46.73 USD
+0.44 (+0.95%)
At close:
46.73 USD
0 (0%)
After Hours:
The current stock price of SRRK is 46.73 USD. Today SRRK is up by 0.95%. In the past month the price increased by 8.47%. In the past year, price increased by 41.99%.
SRRK Key Statistics
52-Week Range27.07 - 51.625
Current SRRK stock price positioned within its 52-week range.
1-Month Range45.72 - 51.625
Current SRRK stock price positioned within its 1-month range.
- Market Cap
- 5.368B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.43
- Dividend Yield
- N/A
SRRK Stock Performance
Today
+0.95%
1 Week
-2.85%
1 Month
+8.47%
3 Months
+5.39%
Longer-term
6 Months +57.77%
1 Year +41.99%
2 Years +218.54%
3 Years +630.16%
5 Years +44.45%
10 Years N/A
SRRK Stock Chart
SRRK Stock Screens
SRRK currently appears in the following ChartMill screener lists.
SRRK Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to SRRK. When comparing the yearly performance of all stocks, SRRK is one of the better performing stocks in the market, outperforming 80.82% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
SRRK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SRRK. SRRK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
SRRK Earnings
Next Earnings DateMay 7, 2026
Last Earnings DateMar 3, 2026
PeriodQ4 / 2025
EPS Reported-$0.88
Revenue Reported
EPS Surprise 3.09%
Revenue Surprise %
SRRK Forecast & Estimates
22 analysts have analysed SRRK and the average price target is 59.16 USD. This implies a price increase of 26.6% is expected in the next year compared to the current price of 46.73.
For the next year, analysts expect an EPS growth of 3.9% and a revenue growth 12665.8% for SRRK
Analysts
Analysts87.27
Price Target59.16 (26.6%)
EPS Next Y3.9%
Revenue Next Year12665.8%
SRRK Groups
Sector & Classification
SRRK Financial Highlights
Over the last trailing twelve months SRRK reported a non-GAAP Earnings per Share(EPS) of -3.43. The EPS decreased by -39.43% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-377.94M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -93.49% | ||
| ROE | -153.95% | ||
| Debt/Equity | 0.41 |
Chartmill High Growth Momentum
EPS Q2Q%-44.26%
Sales Q2Q%N/A
EPS 1Y (TTM)-39.43%
Revenue 1Y (TTM)N/A
SRRK Ownership
Ownership
Inst Owners110.69%
Shares114.88M
Float110.59M
Ins Owners2.98%
Short Float %13.4%
Short Ratio9.73
SRRK Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.33 | 349.118B | ||
| AMGN | AMGEN INC | 14.87 | 183.592B | ||
| GILD | GILEAD SCIENCES INC | 14.62 | 158.566B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.08 | 108.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.61 | 78.702B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.26 | 41.165B | ||
| INSM | INSMED INC | N/A | 29.351B | ||
| NTRA | NATERA INC | N/A | 28.968B | ||
| BIIB | BIOGEN INC | 11.37 | 26.515B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.093B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.47 | 24.851B | ||
| MRNA | MODERNA INC | N/A | 19.314B | ||
| INCY | INCYTE CORP | 12.63 | 19.048B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SRRK
Company Profile
Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 289 full-time employees. The company went IPO on 2018-05-24. The company is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
Company Info
IPO: 2018-05-24
SCHOLAR ROCK HOLDING CORP
301 Binney Street, 3rd Floor
Cambridge MASSACHUSETTS 02142 US
CEO: Stuart A. Kingsley
Employees: 289
Phone: 13026587581
SCHOLAR ROCK HOLDING CORP / SRRK FAQ
What does SRRK do?
Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 289 full-time employees. The company went IPO on 2018-05-24. The company is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
What is the current price of SRRK stock?
The current stock price of SRRK is 46.73 USD. The price increased by 0.95% in the last trading session.
What is the dividend status of SCHOLAR ROCK HOLDING CORP?
SRRK does not pay a dividend.
What is the ChartMill technical and fundamental rating of SRRK stock?
SRRK has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of SRRK stock?
SCHOLAR ROCK HOLDING CORP (SRRK) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for SRRK stock?
SCHOLAR ROCK HOLDING CORP (SRRK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.43).
What is the market capitalization of SRRK stock?
SCHOLAR ROCK HOLDING CORP (SRRK) has a market capitalization of 5.37B USD. This makes SRRK a Mid Cap stock.